Funds for Stargardt therapy
SpliceBio SL, a clinical-stage genetic medicines company in Spain, has received $135 million in Series B financing to advance a new therapy for Stargardt disease, an inherited condition that can lead to the progressive loss of vision and blindness. The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from the Roche Venture Fund and existing investors. It will help finance an ongoing Phase 1/2 trial of the company’s lead gene therapy candidate SB-007.
